Search research articles
Contact Us
Filters
Showing results (31-40 of 46) with videos related to
Page
of 5
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 23, 2020
HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients
J H Shim, H S Kim, H Cha, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 27, 2009
Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma
Y Koh, T M Kim, Y K Jeon, et al.
British Journal of Cancer
|
March 5, 2009
Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival
J-S Kim, M-A Kim, T M Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 6, 2013
Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study
J K Lee, J-Y Shin, S Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 3, 2020
Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial
M Schuler, R Berardi, W-T Lim, et al.
Oncogene
|
January 17, 2017
Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition
H S Kim, M Jung, H N Kang, et al.
ESMO Open
|
August 30, 2024
A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17)
E J Kang, Y Yang, S Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2017
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
J J Knox, C H Barrios, T M Kim, et al.
British Journal of Cancer
|
June 19, 2015
Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma
M E Gore, C Szczylik, C Porta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 2, 2017
Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma
H R Kim, H N Kang, H S Shim, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 46) with videos related to
Sort By:
Page
of 5
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 23, 2020
HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients
J H Shim, H S Kim, H Cha, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 27, 2009
Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma
Y Koh, T M Kim, Y K Jeon, et al.
British Journal of Cancer
|
March 5, 2009
Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival
J-S Kim, M-A Kim, T M Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 6, 2013
Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study
J K Lee, J-Y Shin, S Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 3, 2020
Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial
M Schuler, R Berardi, W-T Lim, et al.
Oncogene
|
January 17, 2017
Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition
H S Kim, M Jung, H N Kang, et al.
ESMO Open
|
August 30, 2024
A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17)
E J Kang, Y Yang, S Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2017
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
J J Knox, C H Barrios, T M Kim, et al.
British Journal of Cancer
|
June 19, 2015
Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma
M E Gore, C Szczylik, C Porta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 2, 2017
Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma
H R Kim, H N Kang, H S Shim, et al.
Page
of 5